The Biostatistics Shared Resource (BSR) of the Knight Cancer Institute (Knight) is a cancer-center managed shared resource and provides biostatistics support to basic, clinical and population science researchers who conduct cancer research at OHSU and partner institutions (e.g., Portland VA Medical Center, Kaiser Permanente Center for Health Research). In addition to providing support to individual researchers, the BSR also assists other Knight shared resources in addressing their biostatistics needs. The BSR strives to enhance the scientific quality and statistical sophistication of cancer research through tailored professional consultation at every level and stage of cancer research. By leveraging CCSG support, the Knight institutional commitment, and other cancer specific grant support, the BSR provides a wide range of biostatistics expertise and supports cancer researchers in a cost-effective manner. Support activities are divided into four major categories: (1) pre-award support, (2) post-award support, (3) infrastructure support, and (4) education and training. Pre-award support includes consultation on study and experimental designs, sample size and power analysis, and statistical analysis plan for investigator-initiated clinical protocols and grant proposals. Post-award support includes protocol implementation, data management, statistical analysis, and manuscript preparation. Infrastructure support refers to collaborative projects with other shared resources to enhance the overall research infrastructure, including development and implementation of statistical protocols for high-throughput genetics/genomics studies, clinical research support through participation in the Protocol Review and Monitorihg^System (i.e., Clinical Research Review Committee and Data and Safety Monitoring Committee). Education and training activities include participation in various cancer journal clubs, research-in-progress meetings, short-term biostatistics workshops, didactic courses in clinical trials and statistical genetics, and professional development activities for BSR members. The BSR is highly utilized and has contributed significantly to cancer research conducted at the Knight. In 2009 the BSR assisted a total of 129 projects from 55 investigators from all four research programs, provided a total of 2,562 consulting hours for investigator-support activities. Between 2005 and 2010, the BSR assisted 65 cancer relevant publications (65 published, 9 in press, revision or submitted). The BSR emphasizes research collaboration at the earliest stage possible as most productive research is conducted under a collaborative research environment.

Public Health Relevance

The BSR insures a scientific rigor and integrity of cancer research at every stage of cancer research project, from a concept formation to proposal development, implementation, data and safety monitoring, data management, data analysis, and manuscript preparation. It plays a critical role in dissemination of accurate scientific information to public and contributes to a body of scientific knowledge that enhances public health through increased understanding of cancer biology, etiology and epidemiology, treatment and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-17
Application #
8712382
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
17
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications